Semax

Semax 5 mg - Premium Research Peptide | PeptideHubs What is Semax? Overview In the fields of neuroprotection, cognitive regulation, and central nervous system injury repair, a synthetic heptapeptide derived from an endogenous hormone fragment, possessing both potent neuroprotective and nootropic properties, is becoming a research hotspot—Semax. Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, it is an adrenocorticotropic hormone (ACTH) 4-10 fragment analog. Its core advantage lies in its precise targeting of the central nervous system, achieving a triple effect of neuroprotection, cognitive enhancement, and anti-stress, while being completely non-hormonal. It is a core research tool in neuroscience, cognitive impairment, and brain injury repair. It does not work through hormonal regulation, but rather by targeting and activating neurotrophic factor pathways, inhibiting neuroinflammation, and regulating neurotransmitter secretion, gently protecting neurons and improving cognitive function. It avoids the limitations of traditional neuroprotective drugs, such as weak blood-brain barrier penetration and significant side effects, acting like a "central nervous system guardian," playing an irreplaceable role in research related to stroke, traumatic brain injury, cognitive decline, and optic nerve injury.

The unique advantage of this peptide lies in its perfect balance between "central targeting" and "safety and low toxicity." Compared to traditional neuroprotective drugs (such as edaravone), which have limitations such as low efficiency in penetrating the blood-brain barrier and a tendency to produce systemic side effects, Semax, as a small-molecule linear heptapeptide, can efficiently penetrate the blood-brain barrier through intranasal administration or subcutaneous injection. It preferentially accumulates in the cerebral cortex, hippocampus, amygdala, and other brain regions related to cognition and memory, with very little distribution in peripheral tissues. Simultaneously, through structural optimization, it completely eliminates the hormonal activity of the natural ACTH fragment, does not activate the hypothalamus-pituitary-adrenal (HPA) axis, has no glucocorticoid-like side effects, and exhibits excellent tolerability. Researchers have described it as a "precisely targeted key to the central nervous system," acting only on the damaged and regulatory pathways of the central nervous system without interfering with overall physiological functions. In contrast, traditional neuroprotective drugs are like "broad-spectrum modulators," which, while providing some protection, easily affect peripheral tissues and cause unnecessary side effects.

As a classic research peptide in neuroscience, Semax's research has progressed from cell experiments and animal models to clinical applications. Its effects on neuroprotection, cognitive enhancement, and brain injury repair have been fully validated in Russian clinical studies. It was approved for marketing in Russia in the mid-1990s and included in Russia's "List of Important and Essential Drugs." It is widely used in the clinical treatment and related research of diseases such as stroke, traumatic brain injury, and optic nerve atrophy. It serves as an important bridge connecting basic neuropeptide research and clinical applications. Currently, it has not yet received FDA or EMA approval in Western countries and is mainly used as a research peptide tool.

Semax peptide structure: Amino acid sequence: H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (L-methionine-L-glutamic acid-L-histidine-L-phenylalanine-L-proline-L-glycine-L-proline), abbreviation MEHFPGP, CAS number 80714-61-0, molecular formula C₃₇H₅₁N₉O₁₀S, molecular weight approximately 813.93 Da. It is a linear synthetic heptapeptide, a structurally optimized analog of the 4-10 fragment of endogenous adrenocorticotropic hormone (ACTH), without artificial terminal modifications, and formed by seven natural L-type amino acids linked by peptide bonds.

Its precise and highly functional structural design, with the selection and connection of each amino acid providing a solid foundation for its central targeting, neuroactive activity, and safety, highlights and advantages are as follows:
• Linear heptapeptide small molecule backbone: Composed of seven natural L-type amino acids forming a linear structure with a molecular weight less than 1000 Da, it possesses excellent blood-brain barrier penetration capability. Effective concentrations can be detected in cerebrospinal fluid within 5 minutes after nasal spray administration, reaching peak central concentrations within 15 minutes. It is one of the very few neuroactive peptides that can efficiently enter the brain through non-injection routes. This characteristic allows it to rapidly act on central target sites, exerting neuroprotective and cognitive regulatory effects.

• Optimized ACTH fragment structure: Precisely replicating the core active motif of ACTH fragments 4-10, while structural optimization through the replacement of the C-terminal Trp→Pro completely eliminates the hormonal activity of the natural ACTH fragment, avoiding hormone-related side effects such as activation of the HPA axis and increased cortisol levels. Simultaneously, it retains and enhances its neuroprotective and nootropic activities. This optimization is the core foundation for its "safe and efficient" performance.

• Anti-enzymatic structural design: The C-terminal diproline (Pro) structure creates steric hindrance, shielding the cleavage sites of carboxypeptidase and aminopeptidase in vivo. This extends the in vivo half-life by more than 20 times compared to the natural ACTH 4-10 fragment. The natural fragment has a half-life of only 2-3 minutes, while Semax has a plasma half-life of up to 3.5 hours, and an even longer half-life in cerebrospinal fluid, effectively prolonging its central nervous system action time.

• Endogenous homology advantage: The core active motif is highly homologous to the human natural ACTH fragment, exhibiting no immunogenicity, not triggering antibody reactions, excellent biocompatibility, and good long-term safety, making it suitable for long-term scientific research and observation scenarios.

This ingenious structural design makes Semax a highly efficient, mild, and highly targeted neuroprotective peptide. It can precisely penetrate the blood-brain barrier to act on the central nervous system, while structural optimization avoids the side effects of hormones, and simultaneously possesses good anti-enzymatic ability and biocompatibility. When it binds to specific receptors in central neurons and glial cells, it rapidly activates neurotrophic factor pathways, inhibits neuroinflammation, and initiates neuronal protection and repair processes. Researchers, in elucidating its mechanism of action, are amazed by the "precise targeting and simplification" of the molecular design of this synthetic peptide.

To date, Semax's core research has covered cell experiments, animal models, and clinical applications in Russia. Its effects on neuroprotection, cognitive enhancement, and brain injury repair have been fully validated, and it is widely used in research and clinical treatment of stroke, traumatic brain injury, cognitive impairment, and optic nerve injury. Although it has not yet received FDA or EMA approval for clinical use in Western countries, it has become one of the most valuable research peptides in neuroscience, providing an important tool for the study of the mechanisms of central nervous system diseases and the development of novel drugs.

Semax Peptides and Neuroprotection and Brain Injury Repair: The most core and extensive research value of Semax lies in its potent neuroprotective effects. It can protect and repair various central nervous system injuries (such as cerebral ischemia, traumatic brain injury, and neurodegenerative damage). Through a multi-target synergistic mechanism, it reduces neuronal apoptosis and alleviates nerve damage, providing an important tool for mechanistic research on stroke, traumatic brain injury, and related diseases. Its neuroprotective effects have demonstrated significant advantages in cell experiments, animal models, and Russian clinical studies.

Its core neuroprotective and repair mechanisms are clearly defined, with multiple targets working synergistically:

• Inhibits neuronal apoptosis and protects neuronal integrity: By blocking excessive activation of NMDA receptors, it reduces calcium ion influx, preventing apoptosis and necrosis caused by neuronal calcium overload; simultaneously, it activates the PI3K/Akt and ERK1/2 pro-survival signaling pathways, upregulates the expression of the anti-apoptotic protein Bcl-2, downregulates the expression of the pro-apoptotic proteins Bax and Caspase-3, blocks the mitochondrial-dependent apoptosis cascade, and reduces neuronal death caused by ischemia, hypoxia, and oxidative stress, making it suitable for research on injury models such as cerebral ischemia and traumatic brain injury.

• Upregulates neurotrophic factor expression: Significantly increases the expression of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and their receptors TrkA and TrkB in the hippocampus and cerebral cortex, promoting dendritic spine formation, synapse formation, and synaptic plasticity in hippocampal neurons, enhancing long-term potentiation (LTP) effects. LTP is the molecular basis of learning and memory. It also promotes the proliferation and differentiation of neural stem cells, replenishes damaged neurons, and promotes the repair and reconstruction of neural circuits.

• Improves cerebral blood flow and energy metabolism: Dilates cerebral blood vessels, improves cerebral microcirculation, increases cerebral blood flow to the ischemic penumbra, reduces the infarct area caused by cerebral ischemia, and provides sufficient oxygen and nutrients to damaged neurons. Simultaneously, it enhances mitochondrial ATP production efficiency, improves neuronal energy metabolism disorders caused by cerebral ischemia and aging, and maintains normal neuronal physiological function.

• Clinically validated repair effects: In a clinical trial involving 110 patients with ischemic stroke, Semax (6000 μg/day, two consecutive 10-day courses) significantly increased plasma BDNF levels, accelerated functional recovery, and improved Barthel Index scores, demonstrating a positive effect regardless of the timing of rehabilitation. This study provides strong support for its research value in brain injury repair.

The study confirmed that Semax can significantly exert neuroprotective effects at concentrations of 1-10 μM. Its potent neuroprotective effect and good safety profile make it an ideal research tool in the fields of stroke, traumatic brain injury, and neurodegenerative diseases, especially suitable for research on the mechanisms of central nervous system injury and repair strategies.

Semax peptides and cognitive regulation and anti-stress: In addition to neuroprotection, Semax also possesses significant cognitive regulation and anti-stress functions. Its effects stem from the precise regulation of the central neurotransmitter system and the upregulation of neurotrophic factors, improving learning and memory, enhancing attention, and alleviating anxiety and stress responses. It provides an important tool for research on cognitive impairment and stress-related diseases.

Its core cognitive regulation and anti-stress mechanisms and manifestations include:

• Optimizing cognitive function and improving learning and memory: By upregulating BDNF expression and promoting synaptic plasticity, it improves neural signal transmission between the cerebral cortex and hippocampus, enhances information processing efficiency, and strengthens core cognitive abilities such as learning, memory, attention, and executive function. In animal experiments, Semax significantly improves cognitive decline caused by aging and neurodegenerative diseases. It has also shown good cognitive improvement effects in studies of minimal cerebral dysfunction in children (including attention deficit hyperactivity disorder, ADHD).

• Regulating neurotransmitter balance: It precisely regulates the synthesis, release, and reuptake of multiple neurotransmitters in the central nervous system, upregulates the dopaminergic system, increases dopamine levels in the prefrontal cortex and striatum, and improves attention and executive function; it enhances the cholinergic system, increases acetylcholine levels, inhibits acetylcholinesterase activity, and improves Alzheimer's disease-related cognitive decline; it balances serotonin and norepinephrine levels, alleviates anxiety and depression-like behaviors, and improves emotional stability.

• Powerful anti-stress effect, enhancing the body's adaptability: It can alleviate the long-term negative effects of early stress such as neonatal isolation, improve stress-induced metabolic disorders and abnormal corticosterone stress responses, and restore stress-induced corticosterone release to normal levels. Simultaneously, it enhances the body's adaptability to harmful stimuli such as hypoxia, cerebral ischemia, and anesthesia, reducing stress-mediated nerve damage, making it suitable for research on stress-related neural mechanisms.

• Anti-fatigue and alertness enhancement: It can improve psychological fatigue in monotonous work and high-pressure environments, enhance alertness and work efficiency, and is suitable for research on cognitive endurance in extreme environments. This characteristic also makes it a potential research tool for improving the cognitive endurance of astronauts and military personnel.

Furthermore, long-term use of Semax can lead to "reverse tolerance," i.e., receptor upregulation leading to a gradual increase in effect, and it lacks the "euphoria" of typical stimulants, focusing more on gently enhancing cognitive function. This characteristic makes it suitable for research scenarios related to long-term cognitive regulation.

Semax peptides and their role in central nervous system anti-inflammation and antioxidation:

Semax is a crucial molecule linking neuroprotection with anti-inflammatory and antioxidative effects. Its neuroprotective effects stem not only from direct neuronal protection but also from inhibiting central nervous system inflammation, scavenging free radicals, and reducing neuronal damage caused by inflammation and oxidative stress, providing new insights for research on central nervous system chronic inflammation-related diseases.

Its central nervous system anti-inflammatory and antioxidant mechanisms include:

• Inhibition of central nervous system inflammation: It inhibits excessive activation of microglia, preventing their polarization towards the pro-inflammatory M1 type and promoting their conversion to the anti-inflammatory M2 type, reducing the release of pro-inflammatory factors (TNF-α, IL-1β, IL-6); simultaneously, it blocks the NF-κB inflammatory signaling pathway, inhibits the nuclear translocation of the NF-κB p65 subunit, downregulates the expression of inflammation-related genes, and reduces neuronal damage caused by the inflammatory cascade; furthermore, it protects the integrity of the blood-brain barrier, reduces the entry of peripheral inflammatory cells and inflammatory factors into the central nervous system, and maintains central nervous system homeostasis.

• Powerful Antioxidant Effects: Upregulates the expression and activity of superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT), enhancing the neuronal's own antioxidant capacity. Simultaneously, it directly scavenges reactive oxygen species (ROS) and reactive nitrogen species (RNS), reducing free radical generation caused by ischemia, hypoxia, and toxins, inhibiting lipid peroxidation, and protecting neuronal DNA, cell membranes, and mitochondria from oxidative damage. Furthermore, it inhibits oxidative stress-related aging pathways, delaying the neuronal aging process.

• Synergistic Protective Effects: The anti-inflammatory and antioxidant effects work synergistically, reducing the mutual promotion of central chronic inflammation and oxidative stress, protecting neurons from multiple dimensions, and delaying the progression of neurodegenerative diseases (such as Alzheimer's disease). It is suitable for collaborative research on central chronic inflammation and neurodegenerative diseases.

Animal studies have confirmed that Semax can significantly reduce central nervous system inflammation and oxidative stress damage. When used in combination with other neuroprotective peptides (such as BPC-157), its anti-inflammatory and neuroprotective effects are even more pronounced. Its triple properties of "neuroprotection + anti-inflammation + antioxidation" make it an ideal tool for multidimensional neuroprotective research.

Semax Peptide and Safety
As a structurally optimized analog of the endogenous ACTH fragment, Semax has demonstrated excellent safety in clinical applications and preclinical studies in Russia, with few and mild adverse reactions. The core risks are related to dosage, administration method, and specific populations, requiring strict limitation to research settings. Furthermore, caution should be exercised regarding the purity of products from unofficial channels:

• Common Reactions: Local reactions are the most common. When administered intranasally, approximately 5%-10% of users experience nasal dryness, mild nasal irritation, and a burning sensation; these are mostly transient reactions that gradually subside as the body adapts. When administered subcutaneously, a small number of users experience mild redness, swelling, and itching at the injection site, with an incidence of approximately 3%-8%. These symptoms completely subside within 24-48 hours after discontinuation of the drug, with no long-term adverse effects.

• Potential Risks: High doses (>1200 μg/day) may cause mild anxiety, insomnia, palpitations, and other irritation symptoms, especially in sensitive individuals. These symptoms can be quickly relieved by reducing the dose. Long-term continuous use (>14 days) may lead to psychological dependence (the illusion of "cognitive addiction"). After discontinuation, transient brain fog and loss of motivation may occur, which usually resolve within a few weeks. The sequence contains methionine (Met), which is easily oxidized and inactivated; improper storage may lead to decreased activity. In diabetic patients, approximately 7% may experience elevated blood glucose levels, requiring blood glucose monitoring and adjustment of hypoglycemic medication dosage.

• Drug Interactions: When used in combination with stimulants (such as amphetamines), it may enhance dopamine release and increase the stimulating effect; caution is required. When used in combination with SSRIs (antidepressants), it may increase serotonin metabolite levels; monitoring for overstimulation symptoms is necessary. When used in combination with neuroprotective peptides such as BPC-157, it may produce a synergistic neuroprotective effect without affecting the biological activity of each other. No obvious adverse reactions are observed when used in combination with antihypertensive drugs.

Significant adverse interactions were observed.

• Important Reminder: Semax has only been approved for clinical use in Russia and some CIS countries. It has not yet been approved for human treatment by Western regulatory agencies such as the FDA and EMA, and is only for research purposes (laboratory analysis, cell experiments, animal model studies). Products from unofficial channels may have insufficient purity, methionine oxidation, or component deviations, seriously affecting research safety and experimental reproducibility. Methionine in its sequence is easily oxidized and must be stored strictly in a cool, dark place. Use is not recommended for pregnant women, breastfeeding women, children under 7 years old, those with a history of epilepsy, or those with acute mental disorders.

Overall, Semax is well-tolerated at standard research doses (400-6000 μg/day intranasally, 300-800 μg/day subcutaneously). Its optimized structural design effectively avoids the side effects of hormones and has no physiological addictive properties. It is a safe and reliable research tool in the field of neuroscience. However, caution is required for use in special populations and special research models, and the source and purity of the product must be strictly controlled.

Future Semax Research and Clinical Trials

As a multifunctional neuroprotective and nootropic peptide, the research boundaries of Semax continue to expand. Currently, multiple cell experiments, animal experiments, and clinical studies in Russia have been conducted, and multi-center studies in the West are also progressing gradually. Its scientific value in multiple fields continues to be explored. Core research directions revolve around neuroprotective mechanisms, indication expansion, dosage form optimization, and Western clinical validation:

• Completed studies: Cell and animal experiments on neuroprotective mechanisms (inhibition of neuronal apoptosis, upregulation of neurotrophic factors), cognitive regulation and anti-stress effects, central anti-inflammatory and antioxidant effects; Russian clinical studies have clarified its therapeutic efficacy and safety in ischemic stroke, traumatic brain injury, optic nerve atrophy, and cognitive impairment; studies on its synergistic effects with other neuroprotective peptides have been completed, providing a foundation for combination drug research; studies on its structure and receptor binding mechanisms have also been completed, providing support for molecular design.

• Ongoing Research: Western multicenter Phase III clinical trials are underway to verify its safety and efficacy in stroke and cognitive impairment, aiming to secure FDA and EMA approvals; nasal administration formulation optimization is being implemented to improve bioavailability and duration of action; development of Semax derivatives (such as N-acetylSemax) is underway to further enhance stability and activity; research is being conducted on its application in neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Rett syndrome; and long-term safety monitoring is being conducted to refine safety data according to Western standards.

• Cutting-Edge Research: Research on the repair effects of Semax in optic nerve and spinal cord injuries; exploration of its synergistic effects in nerve regeneration when combined with stem cell technology; development of oral formulations to overcome limitations in administration methods and expand research applications; exploration of its potential value in pain management and the treatment of depression and anxiety; and exploration of its regulatory mechanisms on the neuroimmune network, providing new directions for research on central nervous system inflammation-related diseases.

Current research focuses on validating its safety and efficacy through multicenter clinical trials in the West, optimizing dosage forms and derivatives, expanding new research indications, and clarifying its underlying mechanisms of action in neurodegenerative diseases and spinal cord injuries. This aims to provide more precise and efficient tools for precision research on central nervous system diseases and the development of novel neuroprotective drugs, driving breakthroughs in neuroscience.

Our Semax has the following significant characteristics:

• Guaranteed purity: Each batch of product undergoes dual testing by HPLC and mass spectrometry, with a purity ≥99%. Verified by an independent third-party laboratory, it is free from bacterial contamination, impurities, and methionine oxidation products, ensuring the accuracy and reliability of research data. It is a white to off-white loose powder, easily soluble in water, PBS, and physiological saline. The aqueous solution is clear, consistent with the typical physicochemical characteristics of Semax. Its pH range is 4.0-7.5, suitable for research experiments under physiological conditions.

• Precise Dosage: 5 mg vials, tailored to research dosage requirements, allowing for flexible configuration of different concentrations according to experimental protocols (e.g., 1-10 μM for cell experiments, 0.04%-0.6% for intranasal administration, 30-80 μg/mL for subcutaneous injection), avoiding dosage waste and meeting the needs of various research scenarios such as cell experiments, animal models, combination drug studies, and intranasal administration experiments.

• Superior Stability: Lyophilized powder formulation, strictly adhering to GMP-grade production standards, can be stored for extended periods (≥2 years) under dry, light-protected, and sealed conditions at -20℃, effectively protecting methionine from oxidation and maintaining peptide chain activity; after reconstitution, it is stable for 7 days at 4℃ and 24 hours at room temperature, adapting to the transportation and storage conditions of laboratories worldwide, avoiding peptide chain degradation and oxidative inactivation that could affect experimental reproducibility.

• Structural Purity: Utilizing a standard synthesis process, the natural amino acid sequence of Semax (MEHFPGP) is precisely replicated. It is an L-type linear heptapeptide, unmodified, completely eliminating hormonal activity and ensuring binding activity to central neuronal receptors, neuroprotective and nootropic effects. The sequence is completely identical to that of Semax used in clinical research, guaranteeing experimental reproducibility.

• Research Use Only: Clearly labeled "For Research Use Only," strictly limited to cell experiments, animal models, and research on neuroprotection, cognitive regulation, and central nervous system inflammation mechanisms. Non-research use is strictly prohibited. A complete quality control report, reconstitution guide, and storage instructions are provided, reminding researchers to avoid light and high temperatures during experimental procedures to prevent methionine oxidation. Precise concentrations are specified according to the administration method.

For researchers exploring central nervous system injury repair, cognitive regulation, and central nervous system inflammation mechanisms, Semax is undoubtedly a key tool molecule for unlocking neuroprotective potential and driving breakthroughs in neuroscience research. Its central targeting, potent activity, and good safety profile make it one of the most valuable research peptides in neuroscience, widely used in life sciences, pharmaceutical development, and neurorehabilitation.